<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02516657</url>
  </required_header>
  <id_info>
    <org_study_id>437619-6</org_study_id>
    <nct_id>NCT02516657</nct_id>
  </id_info>
  <brief_title>Liraglutide in Adolescents With Type 1 Diabetes</brief_title>
  <official_title>Effect of Liraglutide on Glycemic Control, Glucagon Secretion and Inflammatory Markers in Adolescents With Type 1 Diabetes Mellitus</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University at Buffalo</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University at Buffalo</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to study the effect of a liraglutide, a glucagon-like peptide
      agonist, on post-meal blood glucose concentrations, glucagon levels, mean weekly blood
      sugars, and insulin doses in adolescents with Type 1 diabetes. Type 1 diabetes is an
      autoimmune disease that is usually diagnosed before the age of 20. Individuals with this
      disease are completely dependent on insulin for survival. While significant advances have
      been made in technological support for improving diabetes control, insulin remains the only
      effective treatment for Type 1 diabetes. Liraglutide is a long-acting glucagon-like peptide-1
      analog. This drug is approved for the treatment of Type 2 diabetes in adults. This study will
      test the effect of liraglutide on blood sugar control in adolescents with Type 1 diabetes.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>May 2012</start_date>
  <completion_date type="Anticipated">December 2021</completion_date>
  <primary_completion_date type="Anticipated">December 2021</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Mean weekly blood glucose</measure>
    <time_frame>2 weeks</time_frame>
    <description>The primary outcome is to determine whether liraglutide decreases mean weekly blood glucose in adolescents with Type 1 diabetes</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Total Daily insulin dose</measure>
    <time_frame>2 weeks</time_frame>
    <description>U/kg/day</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Blood sugar &lt; 70 mg/dL</measure>
    <time_frame>2 weeks</time_frame>
    <description>Determine whether liraglutide increases episodes of blood sugar &lt;70 mg/dL as measured by glucometer and CGM</description>
  </other_outcome>
  <other_outcome>
    <measure>Amylase level</measure>
    <time_frame>2 weeks</time_frame>
    <description>Determine amylase levels during liraglutide treatment</description>
  </other_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">15</enrollment>
  <condition>Type 1 Diabetes</condition>
  <arm_group>
    <arm_group_label>Liraglutide 0.6 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Liraglutide 0.6 mg daily injection x 7 days</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Liraglutide</intervention_name>
    <description>Liraglutide 0.6 mg</description>
    <arm_group_label>Liraglutide 0.6 mg</arm_group_label>
    <other_name>Victoza</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diagnosis of Type 1 Diabetes Mellitus greater than 1 year

          -  Insulin regimen - continuous subcutaneous insulin infusion with continuous glucose
             monitoring device

          -  HbA1c &lt;10%

        Exclusion Criteria:

          -  Previous exposure to liraglutide

          -  History of abdominal surgery

          -  Gastrointestinal reflux disease

          -  History of acute or chronic pancreatitis

          -  History of alcohol abuse or unwillingness to abstain from alcohol during the study

          -  History of thyroid cancer

          -  Family history of Multiple Endocrine Neoplasia 2B syndrome

          -  Pregnant/breastfeeding females

          -  Individuals with antibody-negative insulin requiring diabetes that is consistent with
             Monogenic Diabetes of Youth

          -  Individuals with steroid induced or cystic fibrosis related diabetes
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>15 Years</minimum_age>
    <maximum_age>21 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Lucy D Mastrandrea, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University at Buffalo</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Lucy D Mastrandrea, MD, PhD</last_name>
    <phone>716-323-0160</phone>
    <email>lmastrandrea@upa.chob.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>UBMD Pediatrics, Division of Pediatric Endocrinology</name>
      <address>
        <city>Buffalo</city>
        <state>New York</state>
        <zip>14203</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lucy D Mastrandrea, MD, PhD</last_name>
      <phone>716-323-0160</phone>
      <email>lmastrandrea@upa.chob.edu</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2019</verification_date>
  <study_first_submitted>August 4, 2015</study_first_submitted>
  <study_first_submitted_qc>August 4, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 6, 2015</study_first_posted>
  <last_update_submitted>September 13, 2019</last_update_submitted>
  <last_update_submitted_qc>September 13, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">September 17, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University at Buffalo</investigator_affiliation>
    <investigator_full_name>Lucy D. Mastrandrea</investigator_full_name>
    <investigator_title>Associate Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 1</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Liraglutide</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

